title: Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
authors: Inga-Marie
authors: IM
authors: Schaefer
authors: Alexander
authors: A
authors: Marx
authors: Christian
authors: C
authors: Sauer
authors: Karin
authors: K
authors: Hohloch
authors: B Michael
authors: BM
authors: Ghadimi
authors: Lorenz
authors: L
authors: Trümper
authors: Philipp
authors: P
authors: Ströbel
mesh_terms: D000199:Actins / Q000378:metabolism; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001158:Arteries / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D006818:Hyalin / Q000378:metabolism; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects*; D000069283:Rituximab; D013154:Spleen / Q000098:blood supply / Q000000981:diagnostic imaging / Q000187:drug effects*; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000199:Actins; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000069283:Rituximab; D008775:Methylprednisolone